Business Wire

FESCIOF

10.3.2023 00:11:39 CET | Business Wire | Press release

Share
FESCIOF concludes after convening more than 100 international organizations, forging a roadmap for effective collaboration and sustainable solutions

The Future of Education, Science, and Culture International Organizations Forum (FESCIOF) successfully ended its inaugural convening in Riyadh, uniting for the first time the Arab League Educational, Cultural and Scientific Organization (ALECSO), the Islamic World Educational, Scientific and Cultural Organization (ICESCO), and the United Nations Educational, Scientific and Cultural Organization (UNESCO) plus more than 100 international organizations, leveraging the power of collaboration to drive meaningful impact for the future of international organizations in the fields of education, science, and culture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005847/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(from left to right) H.E. Mohamed Ould Amar, Director General, ALECSO, H.E. Dr. Salim Al Malik, ICESCO and Costanza Farina, Director, Regional Bureau for Education in the Arab States – UNESCO Representative to Lebanon and Syria (Photo: AETOSWire)

After the forum concluded, the organizers announced their commitment to facilitate further collaboration among international organizations in education, science, and culture. They affirmed the importance of FESCIOF as an innovative effort to align efforts and maximize positive impact through collaboration. Saudi Arabia also took the initiative to host the next two editions of FESCIOF, in 2025 and 2027.

FESCIOF, which featured more than 20 panel sessions with more than 65 speakers under the theme of “Together for Impact in the 21st Century,” aimed to foster insightful discourse and facilitate knowledge exchange to develop a shared vision and identify opportunities for collaboration.

Alongside high-level representatives from UNESCO, ALECSO, and ICESCO, the event facilitated cross-organizational dialogue within a broad ecosystem of change-makers, featuring speakers and attendees from international organizations, including the Islamic Development Bank (IsDB) Group and the United Nations Development Programme (UNDP), as well as experts and thought leaders in organizational design and management from prestigious academic institutions and prominent organizations, such as Harvard Business School, London Business School, INSEAD Blue Ocean Strategy Institute, Google, and Visa, among others.

The representatives from the education, culture and science international organizations reflected on the discussions during the Forum and highlighted its successes, recognizing the value that partnerships between civil society and the private sector bring to the world. During the final session “Preparing the Ground for Future Collaboration,” the panelists, H.E. Mohamed Ouled Amar, Director General of ALECSO; H.E. Dr. Salim Al-Malik, Director General of ICESCO; Costanza Farina, Director Regional Bureau in Beirut and Representative of UNESCO to Lebanon and Syria, emphasized the need to continue working together to create a “Together for Impact” roadmap to achieve shared goals and create a better future for all.

“As organizations and those who are organizing, we need to work at the right time and the right place because the challenge is the value of time,” H.E. Al-Malik said. He also praised the objectives of FESCIOF and said that ICESCO will maximize the conference outcomes and “convert them into action.”

Farina highlighted the interdependence of the three sectors of education, culture, and science, stressing, “we cannot advance on education if we do not advance in science and in culture at the same time.”

Finally, H.E. Mohamed Ould Amar, Director General of ALECSO concluded that “the goals from this Forum are crystal clear, we are working together to achieve them.”

FESCIOF aims to establish a collaborative and trusted global platform for international organizations to come together and capitalize on future opportunities. The event fosters open dialogue and partnership among stakeholders to create a roadmap for international organizations to collaborate more effectively, while establishing a sustainable mechanism for partnerships resulting from the forum.

FESCIOF, which took place from 8-9 March, is jointly organized by the ALECSO and the SNC.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005847/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye